Santen Launches Ryjunea® in Germany for the Treatment of Pediatric Myopia

July 22, 2025 - Osaka, Japan – Following European Commission approval on June 2, 2025, Santen Pharmaceutical Co., Ltd. (hereinafter Santen) today announced that Ryjunea®  (development code: STN1012701), is now available in Germany. Germany is the first market to launch Ryjunea®, with other launches across Europe to follow.

Pediatric myopia, or short-sightedness, is on the rise globally, with increasing screen time and reduced time spent outdoors contributing to worsening vision in young people.^2-5 Myopia progression is typically fastest in younger children, so treatment is needed as early as possible to slow this progression and to reduce the risk of serious eye health complications later in life.^6-8 Parents and pediatricians can play an important role in identifying the issue early.⁹ At the same time, ophthalmologists can intervene to proactively control myopia, helping to reduce myopia risks and support children’s overall social and physical well-being.⁸

For the full story and references, click here to visit Santen’s news story or you can click here for a PDF version of the news story.

Shared by Tyler Stowater, board member of Sydnexis, Inc.